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Dear Editor
Caspase-2 is the most conserved member of the caspase
family, but its physiological function(s) remains a matter of
some debate [1]. Recent work suggests that caspase-2
deficiency in mice makes animals more susceptible to
tumorigenesis in various models leading to the concept that
caspase-2 is a tumor suppressor [1–3]. One of the key
characteristics of caspase-2 knockout (KO) MEFs in culture
and cells from caspase-2-deficient tumors is a high degree
of chromosomal instability (CIN), suggesting that caspase-2
prevents accumulation of aneuploid cells and CIN [1–4].
Real time imaging of KO cells following prolonged spindle-
assembly checkpoint arrest suggests that caspase-2 is
required for the deletion of cells carrying mitotic aberrations
and this requires the catalytic function of caspase-2 [5].
Another model that may explain increased CIN is suggested
by Fava et al. [6]. Their data suggest that supernumerary
centrosomes trigger PIDDosome (a caspase-2 activating
platform containing Pidd and Raidd)-dependent caspase-2
activation, which then cleaves MDM2, resulting in
p53 stabilization and p21-dependent cell cycle arrest [6].
Thus PIDDosome-mediated caspase-2 activation is pre-
dicted to be required to restrain polyploidization, preventing
CIN, and therefore cancer. The main caveat with such a
model is that, unlike Casp2 KO animals, Pidd and Raidd
KO mice are not susceptible to enhanced tumourigenesis
indicating that PIDDosome is not responsible for the tumor
suppressor function of caspase-2 [7, 8].
Most of the studies by Fava et al. used A549 lung ade-
nocarcinoma cells, likely because it is a good in vitro model
for cell cycle studies. To examine this pathway in other cell
types, we generated CASP2 KO U2OS (human osteo-
sarcoma with wild-type p53) cells and compared them with
A549 cells following treatment with the Aurora kinase B
(AURKB) inhibitors, ZM447439 (as used by Fava et al.) or
AZD1152-HQPA, to induce cytokinesis failure (Suppl.
Fig. S1a). AZD1152-HQPA is >3000 times more specific
toward AURKB compared with AURKA, while ZM447439
used by Fava et al. in most of their studies has lower
selectivity [9]. The results confirm some of the observations
reported by Fava et al., including MDM2 cleavage and
increased levels of p53 and p21 in parental cells treated with
the inhibitors (Fig. 1a). We did not observe any difference
between the two AURKB inhibitors. Fava et al. [6] found
that CASP2 KO in A549 cells results in complete abroga-
tion of MDM2 cleavage, p53 accumulation, and cell cycle
arrest of tetraploid cells following cytokinesis failure. Our
data are also consistent with these findings in CASP2 KO
A549 cells (Fig. 1a). However, we observed that CASP2
KO U2OS cells, still showed increased p53 levels that
appear to be independent of MDM2 cleavage in response to
the AURKB inhibitors (Fig. 1a). The p53 response was not
as robust as in the parental U2OS cells, as indicated by
reduced p21 levels in the absence of caspase-2, and this has
previously been documented [1, 4]. Interestingly, we also
observed that MDM2 cleavage increases at 24 h and then
decreases at 48 h following treatment in the non-
synchronized A549, but not in U2OS cells (Suppl.
Fig. S1b), which is consistent with previous data [6]. The
data here, suggest different responses to AURKB inhibition
in different cell types. From a functional perspective, DNA
content analysis of CASP2KO U2OS cells treated with
AZD1152-HQPA showed increased accumulation of poly-
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However, these results are not as dramatic as reported for
A549 cells. In particular, only marginal differences were
observed at 24 h following treatment with AZD1152-HQPA
(Fig. 1b). We found that U2OS cells are efficiently blocked
in cytokinesis by AZD1152-HQPA, ruling out any possi-
bility that the observations are affected by asynchronous
cell populations (Suppl. Fig. S1c). Our data indicate that
cytokinesis failure can trigger p53-mediated cell cycle arrest
in the absence of caspase-2. This suggests the presence of
alternative pathways and cell-type specific differences may
drive caspase-2 responses to prevent polyploidization.
As AURKB has various functions in mitosis including
mitotic condensation, spindle-assembly checkpoint and
cytokinesis [10], inhibiting AURKB by drugs such as
AZD1152-HQPA can cause not only cytokinesis failure but
also prolonged mitosis [11] and DNA damage, that can
induce a p53 response and lead to cell cycle arrest. This, in
turn may also contribute to differential responses to these
drugs in different cell types [12].
In conclusion, we found that MDM2 cleavage in
response to cytokinesis failure is not essential for cell cycle
arrest and p53 accumulation in all cell types. Importantly,
p53-mediated cell cycle arrest can still occur in the com-
plete absence of caspase-2.
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U2OS A549Fig. 1 Aurora kinase B
inhibition results in p53
accumulation in both parental
and CASP2 KO U2OS cells.
U2OS and A459 cells were
synchronized in G1/S by
treatment with 2 mM thymidine
for 24 h. After 3 h release, the
cells were treated with DMSO or
AURKB inhibitors (400 nM
AZD1152-HQPA (AZD) or
2 µM ZM447439 (ZM)) for 0,
24, and 48 h, followed by
immunoblot and fluorescence-
activated cell sorting (FACS)
analyses. a Representative
immunoblots of cell lysates from
treated parental and CASP2 KO
cells. Antibodies used for
immunoblotting are as indicated.
b Percentage of U2OS parental
and CASP2 KO cells with
polyploid (>4N) DNA content
following AZD treatment.
Async, asynchronous
p53 accumulation following cytokinesis failure in the absence of caspase-2 2051
6. Fava LL, Schuler F, Sladky V, Haschka MD, Soratroi C, Eiterer
L, et al. The PIDDosome activates p53 in response to super-
numerary centrosomes. Genes Dev. 2017;31:34–45.
7. Manzl C, Peintner L, Krumschnabel G, Bock F, Labi V, Drach M,
et al. PIDDosome-independent tumor suppression by caspase-2.
Cell Death Differ. 2012;19:1722–32.
8. Peintner L, Dorstyn L, Kumar S, Aneichyk T, Villunger A, Manzl C.
The tumor-modulatory effects of caspase-2 and Pidd1 do not require
the scaffold protein Raidd. Cell Death Differ. 2015;22:1803–11.
9. Marugan C, Torres R, Lallena MJ. Phenotypic screening
approaches to develop aurora kinase inhibitors: drug discovery
perspectives. Front Oncol. 2015;5:299.
10. Goldenson B, Crispino JD. The aurora kinases in cell cycle and
leukemia. Oncogene. 2015;34:537–45.
11. Tsuda Y, Iimori M, Nakashima Y, Nakanishi R, Ando K, Ohgaki
K, et al. Mitotic slippage and the subsequent cell fates after
inhibition of Aurora B during tubulin-binding agent-induced
mitotic arrest. Sci Rep. 2017;7:16762.
12. Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM,
et al. Targeting aurora kinases limits tumour growth through
DNA damage-mediated senescence and blockade of NF-kappaB
impairs this drug-induced senescence. EMBO Mol Med. 2013;5:
149–66.
2052 Y. Lim et al.
